Journal of Clinical Trials
Open Access
ISSN: 2167-0870
+44 1478 350008
ISSN: 2167-0870
+44 1478 350008
Amorphical LTD, Nes-Ziona, Israel
Research Article
Sublingual and Inhaled Amorphous Calcium Carbonate for Hospitalized Patients with SARS-CoV-2: A Phase 1/2 Clinical Study
Author(s): Nashat Abu Saleh, Yigal Blum*, Albert El-Roeiy, Yafit Stark, Kamal Abu Jabal and Frederic Deutch
Background: Novel medications for treating any SARS-CoV-2 variant and similar pandemic viruses are sought. Growing evidence connects coronavirus’ binding, fusion, and replication, as well as evolved acute pulmonary infections, with locally induced acidity. Stabilized Amorphous Calcium Carbonate (ACC) has demonstrated preclinical and clinical efficacies for treating biomedical conditions associated with pH modulation effects by delivering alkaline carbonate content to acidified environments.
Objectives: The study aimed to establish the safety, tolerability, and efficacy of ACC, named AMOR-18 (manufactured by Amorphical LTD), for treating hospitalized patients with moderate-to-severe SARS-CoV-2, administered as a combination of sublingual powder and inhaled suspensions alongside the Best Available Treatment (BAT).
Metho.. View More»
DOI:
10.35248/2167-0870.23.13.538